Get the Stockscreener App
2.075
9.78%
-0.225
Pre-market:
2.08
0.005
+0.24%
Pepgen Inc stock is traded at $2.075, with a volume of 704.40K.
It is down -9.78% in the last 24 hours and down -42.84% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$2.30
Open:
$2.33
24h Volume:
704.40K
Relative Volume:
4.05
Market Cap:
$67.64M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.6987
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
-23.71%
1M Performance:
-42.84%
6M Performance:
-87.46%
1Y Performance:
-69.17%
1-Day Range:
$2.07
$2.44
1-Week Range:
$2.07
$2.83
52-Week Range:
$2.07
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
2.075 | 67.64M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PepGen stock hits 52-week low at $2.21 amid market challenges - MSN
PepGen Inc. (NASDAQ:PEPG) Short Interest Down 14.1% in December - MarketBeat
PepGen stock hits 52-week low at $2.88 amid market challenges - Investing.com India
PepGen stock hits 52-week low at $2.88 amid market challenges By Investing.com - Investing.com South Africa
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - AccessWire
Jane Street Group LLC Purchases 6,254 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy - Yahoo Finance
Barclays PLC Has $189,000 Stock Position in PepGen Inc. (NASDAQ:PEPG) - Defense World
Geode Capital Management LLC Has $3.21 Million Stock Holdings in PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Comments on PepGen’s FY2028 Earnings (NASDAQ:PEPG) - Defense World
Fmr LLC Sells 327,160 Shares of PepGen Inc. (NASDAQ:PEPG) - Defense World
Wedbush Has Bullish Forecast for PepGen FY2028 Earnings - MarketBeat
FDA Pauses PepGen’s DMD Drug Trial in the US - AJMC.com Managed Markets Network
PepGen stock craters 35% on FDA clinical hold - MSN
PepGen (NASDAQ:PEPG) Downgraded by Bank of America to Underperform - Defense World
FDA halts PepGen's DMD trial; ongoing study continues By Investing.com - Investing.com Australia
PepGen stock touches 52-week low at $2.9 amid market challenges - Investing.com
FDA halts PepGen's DMD trial; ongoing study continues - Investing.com India
PepGen shares downgraded to Underperform by BofA amid uncertainty over clinical hold - Investing.com
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
PepGen stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
Déjà Vu for PepGen as FDA Places Hold on DMD Drug - BioSpace
PepGen Shares Tumble Premarket as FDA Puts Study on Clinical Hold - MarketWatch
FDA Places Clinical Hold on PepGen's Phase 2 DMD Trial, Canadian Study Advances - StockTitan
When (PEPG) Moves Investors should Listen - Stock Traders Daily
Frazier Life Sciences Management L.P. Sells 800,094 Shares of PepGen Inc. (NASDAQ:PEPG) - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Shares Bought by Janus Henderson Group PLC - MarketBeat
PepGen Inc. (NASDAQ:PEPG) Shares Acquired by Suvretta Capital Management LLC - MarketBeat
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - Yahoo Finance
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development - Business Wire
Two new option listings and one option delisting on November 21st - TipRanks
Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation - Simply Wall St
BofA lowers PepGen stock target as trial delays and competition weigh on outlook - Investing.com
Bank of America Cuts PepGen (NASDAQ:PEPG) Price Target to $6.00 - MarketBeat
PepGen price target lowered to $6 from $10 at BofA - TipRanks
Janus Henderson Group PLC's Strategic Acquisition of PepGen Inc Shares - GuruFocus.com
Leerink Partnrs Issues Positive Forecast for PepGen Earnings - MarketBeat
PepGen (NASDAQ:PEPG) Price Target Cut to $12.00 by Analysts at Wedbush - MarketBeat
PepGen (NASDAQ:PEPG) Earns "Buy" Rating from HC Wainwright - MarketBeat
PepGen Inc (PEPG) Quarterly 10-Q Report - Quartz
PepGen reports Q3 EPS (66c), consensus (87c) - TipRanks
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - BioSpace
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate - Yahoo Finance
Objective long/short (PEPG) Report - Stock Traders Daily
PepGen to Participate in Upcoming Investor Conferences - Business Wire
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):